Neuland Laboratories Ltd
Q1 FY27, unaudited
- Revenue
- ₹641.58 Cr
- Profit after tax
- ₹147.36 Cr
As filed with the exchange, standalone basis.
Statement of profit and loss
Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.
| ₹ crore | Q1 FY27 | vs a year ago | FY26 |
|---|---|---|---|
| Revenue from operations | 641.58 | +119.15% | 2,022.99 |
| Other income | 8.49 | +8.09% | 30.16 |
| Total income | 650.07 | +116.25% | 2,053.15 |
| Employee benefit expense | 103.02 | +45.35% | 328.82 |
| Finance costs | 6.97 | +52.12% | 23.95 |
| Depreciation & amortisation | 26.56 | +31.57% | 91.73 |
| Total expenses | 452.53 | +59.78% | 1,565.42 |
| Profit before tax | 197.54 | +1,036.70% | 487.73 |
| Tax expense | 50.17 | +1,266.99% | 124.63 |
| Profit after tax | 147.36 | +975.04% | 363.11 |
| Total comprehensive income | 147.36 | +975.04% | 363.46 |
| Earnings per share, basic | ₹114.86 | ₹283.01 |
|---|---|---|
| Earnings per share, diluted | ₹114.86 | ₹283.01 |
Earnings call
Q1 FY27Neuland Laboratories reported total income of INR650.1 crores for Q1FY27, up 16.3% year-on-year, with EBITDA margin at 35.5% and PAT of INR147.4 crores compared to INR13.7 crores a year earlier. Management attributed growth primarily to commercial CMS projects and a favorable customer mix, while working capital days improved from 137 to 84. The company also discussed a strategic collaboration with Gland Pharma for sterile API manufacturing and progress on its peptide manufacturing facility, which is expected to be commissioned the following month.
Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote. Read the cited summary
Earlier calls: Q4 FY26 · All quarters
Filings
12 shown · 56 published by the exchange
25 Aug 2026
Credit rating23 Aug 2026
Filing17 Aug 2026
14 Aug 2026
10 Aug 2026
Transcript07 Aug 2026
06 Aug 2026
Filing05 Aug 2026
05 Aug 2026
FilingDisclosure Under Regulation 30 Of SEBI Listing Regulations
Appears 2 times in the recent filings shown; listed once.
05 Aug 2026
Presentation05 Aug 2026
05 Aug 2026
BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.
Page generated from filings held to 25 Aug 2026.